GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Market Cap

GlobeImmune (GlobeImmune) Market Cap : $0.00 Mil (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GlobeImmune's share price for the quarter that ended in Mar. 2016 was $2.09. GlobeImmune's Shares Outstanding (EOP) for the quarter that ended in Mar. 2016 was 5.75 Mil. Therefore, GlobeImmune's market cap for the quarter that ended in Mar. 2016 was $12.02 Mil.

GlobeImmune's quarterly market cap increased from Sep. 2015 ($15.01 Mil) to Dec. 2015 ($22.26 Mil) but then declined from Dec. 2015 ($22.26 Mil) to Mar. 2016 ($12.02 Mil).

GlobeImmune's annual market cap increased from Dec. 2013 ($0.00 Mil) to Dec. 2014 ($43.65 Mil) but then declined from Dec. 2014 ($43.65 Mil) to Dec. 2015 ($22.26 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GlobeImmune's Enterprise Value for Today is $0.00 Mil.


GlobeImmune Market Cap Historical Data

The historical data trend for GlobeImmune's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune Market Cap Chart

GlobeImmune Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Market Cap
Get a 7-Day Free Trial - - - 43.65 22.26

GlobeImmune Quarterly Data
Dec10 Mar11 Jun11 Dec11 Mar12 Jun12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.22 15.01 15.01 22.26 12.02

Competitive Comparison of GlobeImmune's Market Cap

For the Biotechnology subindustry, GlobeImmune's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeImmune's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's Market Cap distribution charts can be found below:

* The bar in red indicates where GlobeImmune's Market Cap falls into.



GlobeImmune Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

GlobeImmune's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as

Market Cap (A: Dec. 2015 )=Share Price (A: Dec. 2015 )*Shares Outstanding (EOP) (A: Dec. 2015 )
=$3.87*5.75157
=$22.26

GlobeImmune's Market Cap for the quarter that ended in Mar. 2016 is calculated as

Market Cap (Q: Mar. 2016 )=Share Price (Q: Mar. 2016 )*Shares Outstanding (EOP) (Q: Mar. 2016 )
=$2.09*5.75157
=$12.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlobeImmune  (OTCPK:GBIM) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


GlobeImmune Market Cap Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines